# EDGAR Filing Document

**Accession Number:** 0001824293
**File Stem:** 0001824293-26-000027
**Filing Date:** 2026-1
**Character Count:** 24006
**Document Hash:** 5018d750265b92c409e3a0932634296d
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001824293-26-000027.hdr.sgml**: 20260130

**ACCESSION NUMBER**: 0001824293-26-000027

**CONFORMED SUBMISSION TYPE**: S-8

**PUBLIC DOCUMENT COUNT**: 17

**FILED AS OF DATE**: 20260130

**DATE AS OF CHANGE**: 20260129

**EFFECTIVENESS DATE**: 20260130

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** GRI Bio, Inc.
- **CENTRAL INDEX KEY:** 0001824293
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 824369909
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** S-8
- **SEC ACT:** 1933 Act
- **SEC FILE NUMBER:** 333-293063
- **FILM NUMBER:** 26579956

**BUSINESS ADDRESS:**
- **STREET 1:** 2223 AVENIDA DE LA PLAYA
- **STREET 2:** SUITE 208
- **CITY:** LA JOLLA
- **STATE:** CA
- **ZIP:** 92037
- **BUSINESS PHONE:** (619) 400-1171

**MAIL ADDRESS:**
- **STREET 1:** 2223 AVENIDA DE LA PLAYA
- **STREET 2:** SUITE 208
- **CITY:** LA JOLLA
- **STATE:** CA
- **ZIP:** 92037

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** GRI BIO, Inc.
- **DATE OF NAME CHANGE:** 20230424

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Vallon Pharmaceuticals, Inc.
- **DATE OF NAME CHANGE:** 20200910

**As filed with the Securities and Exchange Commission on January 29, 2026**

**Registration No. 333-**

![image_0.jpg](image_0.jpg)

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549** 

**FORM S-8**

**REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933**

**GRI BIO, INC**.

(Exact name of registrant as specified in its charter)

---

| | |
|:---|:---|
| **Delaware** | **82-4369909** |
| (State or other jurisdiction | (I.R.S. Employer Identification No.) |
| of incorporation or organization) | |

---

**2223 Avenida de la Playa, #208**

**La Jolla, CA 92037**

(Address of principal executive offices and zip code)

**Amended and Restated GRI Bio, Inc. 2018 Equity Incentive Plan**

(Full title of the plan)

**W. Marc Hertz, Ph.D.**

**Chief Executive Officer**

**GRI Bio, Inc.**

**2223 Avenida de la Playa #208**

**La Jolla, CA 92037**

**(619) 400-1170**

(Name,address, including zip code and telephone number including area code of agent for service)

**With Copy to:**

**Adam Lenain, Esq.**

**Melanie Ruthrauff Levy, Esq.**

**Jessica Zhang, Esq.**

**Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C.**

**3580 Carmel Mountain Road, Suite 300**

**San Diego, California 92130**

**Tel: (858) 314-1500**

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company" and "emerging growth company" in Rule 12b-2 of the Exchange Act:

---

| | | | |
|:---|:---|:---|:---|
| Large Accelerated Filer | ☐ | Accelerated Filer | ☐ |
| Non-Accelerated Filer | ☒ | Smaller Reporting Company | ☒ |
| | | Emerging Growth Company | ☒ |

---

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act.☐

![image_0.jpg](image_0.jpg)

![image_8.jpg](image_8.jpg)

------

**EXPLANATORY NOTE**

**Amended and Restated 2018 Equity Incentive Plan**

This Registration Statement on Form S-8 (the "Registration Statement") registers an additional 19,907 shares of common stock, par value $0.0001 per share ("Common Stock"), of GRI Bio, Inc. (the "Registrant"), reserved for issuance pursuant to the Amended and Restated GRI Bio, Inc. 2018 Equity Incentive Plan, as amended (the "2018 Plan"), which includes the aggregate increase in the number of shares reserved under the 2018 Plan by operation of the 2018 Plan's "evergreen provision" on January 1<sup>st</sup> of 2026. This Registration Statement registers additional securities of the same class as other securities for which a registration statement filed on Form S-8 of the Registrant relating to an employee benefit plan is effective (File No. 333-255972). The information contained in the Registrant's registration statements on Form S-8 (File Nos. 333-255972, 333-284149 and 333-289593) is hereby incorporated by reference into this Registration Statement pursuant to General Instruction E of Form S-8.

**PART II**

**INFORMATION REQUIRED IN THE REGISTRATION STATEMENT**

**Item 3. Incorporation of Documents by Reference.**

The following documents, which the Registrant has filed with the Securities and Exchange Commission (the "Commission"), are incorporated herein by reference:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• The Registrant's Annual Report on Form 10-K for the fiscal year ended December 31, 2024, filed with the Commission on <u>[March 14, 2025](https://www.sec.gov/ix?doc=/Archives/edgar/data/1824293/000182429325000050/ck0001824293-20241231.htm)</u>;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• The Registrant's Quarterly Reports on Form 10-Q for the fiscal quarters ended March 31, 2025, June 30, 2025 and September 30, 2025 filed with the Commission on <u>[May 15, 2025](https://www.sec.gov/ix?doc=/Archives/edgar/data/1824293/000182429325000073/ck0001824293-20250331.htm)</u>, <u>[August 14, 2025](https://www.sec.gov/ix?doc=/Archives/edgar/data/1824293/000182429325000106/ck0001824293-20250630.htm)</u> and <u>[November 14, 2025](https://www.sec.gov/ix?doc=/Archives/edgar/data/1824293/000182429325000151/ck0001824293-20250930.htm)</u>, respectively;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• The Registrant's Current Reports on Form 8-K filed with the Commission on <u>[February 11, 2025](https://www.sec.gov/ix?doc=/Archives/edgar/data/1824293/000182429325000039/val-20250211.htm)</u>, <u>[February 19, 2025](https://www.sec.gov/ix?doc=/Archives/edgar/data/1824293/000182429325000042/val-20250219.htm)</u>, <u>[March 11, 2025](https://www.sec.gov/ix?doc=/Archives/edgar/data/1824293/000182429325000045/val-20250310.htm)</u>, <u>[March 17, 2025](https://www.sec.gov/ix?doc=/Archives/edgar/data/1824293/000182429325000053/val-20250317.htm)</u>, <u>[April 2, 2025](https://www.sec.gov/ix?doc=/Archives/edgar/data/1824293/000162828025016066/val-20250401.htm)</u>, <u>[April 1](https://www.sec.gov/ix?doc=/Archives/edgar/data/1824293/000182429325000058/val-20250411.htm)[6](https://www.sec.gov/ix?doc=/Archives/edgar/data/1824293/000182429325000058/val-20250411.htm)[, 2025](https://www.sec.gov/ix?doc=/Archives/edgar/data/1824293/000182429325000058/val-20250411.htm)</u>, <u>[May 5, 2025](https://www.sec.gov/ix?doc=/Archives/edgar/data/1824293/000182429325000063/val-20250505.htm)</u>, <u>[May 15, 2025](https://www.sec.gov/ix?doc=/Archives/edgar/data/1824293/000182429325000072/val-20250515.htm)</u>, <u>[May 23, 2025](https://www.sec.gov/ix?doc=/Archives/edgar/data/1824293/000182429325000079/val-20250523.htm)</u>, <u>[June 26, 2025](https://www.sec.gov/ix?doc=/Archives/edgar/data/1824293/000182429325000082/val-20250626.htm)</u>, <u>[July 31, 2025](https://www.sec.gov/ix?doc=/Archives/edgar/data/1824293/000182429325000094/val-20250731.htm)</u>, <u>[August 13, 2025](https://www.sec.gov/ix?doc=/Archives/edgar/data/1824293/000182429325000096/val-20250813.htm)</u>, <u>[August 20, 2025](https://www.sec.gov/ix?doc=/Archives/edgar/data/1824293/000182429325000126/val-20250820.htm)</u>, <u>[December 2, 2025](https://www.sec.gov/ix?doc=/Archives/edgar/data/1824293/000182429325000155/val-20251126.htm)</u>, <u>[December 8, 2025](https://www.sec.gov/ix?doc=/Archives/edgar/data/1824293/000182429325000160/val-20251208.htm)</u>, <u>[December 10, 2025](https://www.sec.gov/ix?doc=/Archives/edgar/data/1824293/000182429325000167/val-20251210.htm)</u>, <u>[December 12, 2025](https://www.sec.gov/ix?doc=/Archives/edgar/data/1824293/000162828025056659/val-20251211.htm)</u>, <u>[December 12, 2025](https://www.sec.gov/ix?doc=/Archives/edgar/data/1824293/000162828025056751/val-20251212.htm)</u>, <u>[Janu](https://www.sec.gov/ix?doc=/Archives/edgar/data/0001824293/000182429326000002/val-20260108.htm)[ary 8, 2026](https://www.sec.gov/ix?doc=/Archives/edgar/data/0001824293/000182429326000002/val-20260108.htm)</u>, <u>[Janu](https://www.sec.gov/ix?doc=/Archives/edgar/data/0001824293/000182429326000006/val-20260109.htm)[ary 9, 202](https://www.sec.gov/ix?doc=/Archives/edgar/data/0001824293/000182429326000006/val-20260109.htm)[6](https://www.sec.gov/ix?doc=/Archives/edgar/data/0001824293/000182429326000006/val-20260109.htm)</u>, <u>[January 1](https://www.sec.gov/ix?doc=/Archives/edgar/data/0001824293/000182429326000009/val-20260115.htm)[5, 2](https://www.sec.gov/ix?doc=/Archives/edgar/data/0001824293/000182429326000009/val-20260115.htm)[026](https://www.sec.gov/ix?doc=/Archives/edgar/data/0001824293/000182429326000009/val-20260115.htm)</u>, <u>[January 16, 2026](https://www.sec.gov/ix?doc=/Archives/edgar/data/0001824293/000182429326000011/val-20260115.htm)</u>, <u>[January 21, 2](https://www.sec.gov/ix?doc=/Archives/edgar/data/0001824293/000182429326000014/val-20260121.htm)[026](https://www.sec.gov/ix?doc=/Archives/edgar/data/0001824293/000182429326000014/val-20260121.htm)</u> and <u>[January 28, 2026](https://www.sec.gov/ix?doc=/Archives/edgar/data/0001824293/000182429326000017/val-20260128.htm)</u> (except for the information furnished under Items 2.02 or 7.01 and the exhibits thereto); and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• The description of its Common Stock contained in Exhibit 4.21 of its Annual Report on Form 10-K for the year ended December 31, 2024 filed with the Commission on <u>[March 14, 2025](https://www.sec.gov/Archives/edgar/data/1824293/000182429325000050/gri-202410k_ex428.htm)</u>, and any amendment or report filed with the Commission for the purpose of updating such description.

All documents subsequently filed by the Registrant pursuant to Sections 13(a), 13(c), 14, and 15(d) of the Securities Exchange Act of 1934, as amended, prior to the filing of a post-effective amendment that indicates that all shares of Common Stock offered hereby have been sold or which deregisters all shares of Common Stock then remaining unsold, shall be deemed to be incorporated by reference in this Registration Statement and to be part hereof from the date of filing of such documents; provided, however, that documents or information deemed to have been furnished and not filed in accordance with Commission rules shall not be deemed incorporated by reference into this Registration Statement. Any statement contained herein or in a document, all or a portion of which is incorporated or deemed to be incorporated by reference herein, shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained herein or in any other subsequently filed document which also is or is deemed to be incorporated by reference herein modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or amended, to constitute a part of this Registration Statement.

------

**Item 8.&nbsp;&nbsp;&nbsp;&nbsp;Exhibits.**

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| **Exhibit No.** | **Description** | **Filed Herewith** | **Form** | **Incorporated by Reference File No.** | **Date Filed** |
| 4.1 | <u>[Amended and Restated Certificate of Incorporation, as amended.](https://www.sec.gov/Archives/edgar/data/1824293/000182429325000050/gri-202410k_ex31.htm)</u> |  | 10-K | 001-40034 | 3/14/2025 |
| 4.2 | <u>[Certificate of Amendment to the Amended and Restated Certificate of Incorporation, as amended.](https://www.sec.gov/Archives/edgar/data/1824293/000182429326000014/ex31_reversestocksplitchar.htm)</u> |  | 8-K | 001-40034 | 1/21/2026 |
| 4.3 | <u>[Amended and Restated Bylaws.](https://www.sec.gov/Archives/edgar/data/1824293/000182429323000129/gribioinc-amendedandrestat.htm)</u> |  | 8-K/A | 001-40034 | 5/26/2023 |
| 4.4 | <u>[Specimen Common Stock Certificate.](https://www.sec.gov/Archives/edgar/data/1824293/000110465921008880/tm2030737d10_ex4-1.htm)</u> |  | S-1 | 333-249636 | 10/23/2020 |
| 5.1 | <u>[Opinion of Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C.](exhibit51-january 26sx8.htm)</u> | X |  |  |  |
| 23.1 | <u>[Consent of Sadler, Gibb & Associates, LLC, Independent Registered Public Accounting Firm.](exhibit231-january 26sx8.htm)</u> | X |  |  |  |
| 23.3 | <u>[Consent of Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. (included legal opinion filed as Exhibit 5.1).](exhibit51-january 26sx8.htm)</u> | X |  |  |  |
| 24.1 | <u>[Power of Attorney (included on signature page).](#i896cda109940497eb78bbc60562f4639_37)</u> | X |  |  |  |
| 99.1# | <u>[Amended and Restated GRI Bio, Inc. 2018 Equity Incentive Plan, as Amended.](https://www.sec.gov/Archives/edgar/data/1824293/000182429325000096/ex101_2018equitycompplanam.htm)</u> |  | 8-K | 001-40034 | 8/13/2025 |
| 99.2# | <u>[Form of Non-Qualified Stock Option Agreement under the Registrant's Amended and Restated 2018 Equity Incentive Plan.](https://www.sec.gov/Archives/edgar/data/1824293/000110465920117717/tm2030737d4_ex10-6.htm)</u> |  | S-1 | 333-249636 | 10/23/2020 |
| 99.3# | <u>[Form of Incentive Stock Option Agreement under the Registrant's Amended and Restated 2018 Equity Incentive Plan.](https://www.sec.gov/Archives/edgar/data/1824293/000110465920117717/tm2030737d4_ex10-7.htm)</u> |  | S-1 | 333-249636 | 10/23/2020 |
| 99.4# | <u>[Form of Restricted Stock Unit Agreement under the Registrant's Amended and Restated 2018 Equity Incentive Plan.](https://www.sec.gov/Archives/edgar/data/1824293/000182429325000102/exhibit994-august 25sx8.htm)</u> |  | S-8 | 333-289593 | 8/13/2025 |
| 107 | <u>[Filing fee table.](exfilingfees.htm)</u> | X |  |  |  |

---

# Indicates management contract or compensatory plan, contract or arrangement.

**SIGNATURES**

Pursuant to the requirements of the Securities Act of 1933, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the city of La Jolla, state of California on January 29, 2026.

---

| | |
|:---|:---|
| **GRI BIO, INC.** | **GRI BIO, INC.** |
| By: | /s/ W. Marc Hertz, Ph.D. |
|  | W. Marc Hertz, Ph.D. |
|  | President and Chief Executive Officer |

---

------

**POWER OF ATTORNEY**

Each person whose signature appears below constitutes and appoints each of W. Marc Hertz, Ph.D., and Leanne Kelly, acting alone or together with another attorney-in-fact, as his or her true and lawful attorney-in-fact and agent, with full power of substitution and resubstitution, for such person and in his or her name, place and stead, in any and all capacities, to sign any or all further amendments (including post-effective amendments) to this registration statement, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorney-in-fact and agent, or his or her substitute or substitutes, may lawfully do or cause to be done by virtue hereof.

Pursuant to the requirements of the Securities Act of 1933, this registration statement has been signed by the following persons in the capacities and on the dates indicated.

---

| | | |
|:---|:---|:---|
| **Signature** | **Title** | **Date** |
| /s/ W. Marc Hertz, Ph.D. | President, Chief Executive Officer and Director | January 29, 2026 |
| W. Marc Hertz, Ph.D. | *(Principal Executive Officer)* |  |
| /s/ Leanne Kelly | Chief Financial Officer | January 29, 2026 |
| Leanne Kelly | *(Principal Financial and Accounting Officer)* |  |
| /s/ David Szekeres | Director, Chairperson of the Board | January 29, 2026 |
| David Szekeres |  |  |
| /s/ David Baker | Director | January 29, 2026 |
| David Baker |  |  |
| /s/ Roelof Rongen | Director | January 29, 2026 |
| Roelof Rongen |  |  |
| /s/ Camilla V. Simpson, M.Sc. | Director | January 29, 2026 |
| Camilla V. Simpson, M.Sc. |  |  |

---

## Ex-Filing

?xml version='1.0' encoding='ASCII'? exfilingfees

**EX-FILING FEES**

**Calculation of Filing Fee Table**

**Form S-8**

(Form Type)

**GRI Bio, Inc.**

(Exact Name of Registrant as Specified in its Charter)

Table 1: Newly Registered Securities

---

| | | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| **Line Item Type** | **Security Type** | **Security Class Title** | **Fee Calculation or Carry Forward Rule** | **Amount** <br>**Registered**<sup>(1)</sup> | **Proposed** <br>**Maximum Offering Price Per Unit**<sup>(2)</sup> | **Maximum Aggregate** <br>**Offering Price**  | **Maximum Aggregate** <br>**Offering Price**  | **Fee Rate** | **Amount of Registration** <br>**Fee** |
| Fees to be Paid | Equity | Common stock, $0.0001 par value per share | 457(c) and 457(h) | 19907 | $5.515 | $109787.11 | <sup>(2)</sup> | $0.00013810 | $15.16 |
|  | Total Offering Amounts | Total Offering Amounts | Total Offering Amounts | Total Offering Amounts | Total Offering Amounts | $109787.11 |  |  | $15.16 |
|  | Total Fee Offset | Total Fee Offset | Total Fee Offset | Total Fee Offset | Total Fee Offset |  |  |  | – |
|  | Net Fee Due | Net Fee Due | Net Fee Due | Net Fee Due | Net Fee Due |  |  |  | $15.16 |

---

____________

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1)Pursuant to Rule 416(a) and Rule 416(b) under the Securities Act of 1933, as amended (the "Securities Act"), this Registration Statement shall also cover any additional shares of the common stock, par value $0.0001 per share (the "Common Stock"), of GRI Bio, Inc. (referred to herein as the "Registrant", "we," "us" or "our") that becomes issuable under the Registrant's Amended and Restated 2018 Equity Incentive Plan, as amended (the "2018 Plan"), by reason of certain corporate transactions or events, including any share dividend, share split, recapitalization or certain other transactions that result in an increase in the number of the outstanding shares of the Registrant's Common Stock.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(2)Estimated in accordance with Rules 457(c) and (h) of the Securities Act solely for the purpose of calculating the registration fee. The offering price per share and the aggregate offering price for shares reserved for future grant or issuance under the 2018 Plan are based on $5.515 per share, the average of the high and the low price of Registrant's Common Stock as reported on The Nasdaq Capital Market as of a date (January 26, 2026) within five business days prior to filing this Registration Statement.

------

0001824293

## Exhibit 5.1

**Exhibit 5.1**

---

| | |
|:---|:---|
| ![mintzlogo.jpg](mintzlogo.jpg) | 3580 Carmel Mountain Road, Ste 300<br>San Diego, CA 92130<br>858 314 1500<br>mintz.com |

---

January 29, 2026

GRI Bio, Inc.

2223 Avenida de la Playa, Suite 208

La Jolla, CA 92037

Re: <u>Registration Statement on Form S-8</u>

Ladies and Gentlemen:

We have acted as legal counsel to GRI Bio, Inc., a Delaware corporation (the "Company"), in connection with the preparation and filing with the Securities and Exchange Commission (the "Commission") of a Registration Statement on Form S-8 (the "Registration Statement"), pursuant to which the Company is registering the issuance under the Securities Act of 1933, as amended (the "Securities Act"), of an aggregate of 19,907 additional shares (the "Shares") of the Company's common stock, par value $0.0001 per share, that may be issued pursuant to the Company's Amended and Restated 2018 Equity Incentive Plan, as amended (the "2018 Plan"). This opinion is being rendered in connection with the filing of the Registration Statement with the Commission. All capitalized terms used herein and not otherwise defined shall have the respective meanings given to them in the Registration Statement.

In connection with this opinion, we have examined the Company's Amended and Restated Certificate of Incorporation, as amended, and Amended and Restated Bylaws, each as currently in effect; such other records of the corporate proceedings of the Company and certificates of the Company's officers as we have deemed relevant; and the Registration Statement and the exhibits thereto.

In our examination, we have assumed the genuineness of all signatures, the legal capacity of natural persons, the authenticity of all documents submitted to us as originals, the conformity to original documents of all documents submitted to us as copies, the authenticity of the originals of such copies and the truth and correctness of any representations and warranties contained therein. In addition, we have assumed that the Company will receive any required consideration in accordance with the terms of the 2018 Plan.

Our opinion expressed herein is limited to the General Corporation Law of the State of Delaware and we express no opinion with respect to the laws of any other jurisdiction. No opinion is expressed herein with respect to the qualification of the Shares under the securities or blue sky laws of any state or any foreign jurisdiction.

Please note that we are opining only as to the matters expressly set forth herein, and no opinion should be inferred as to any other matters. This opinion is based upon currently existing statutes, rules, regulations and judicial decisions, and we disclaim any obligation to advise you of any change in any of these sources of law or subsequent legal or factual developments which might affect any matters or opinions set forth herein.

Based upon the foregoing, we are of the opinion that the Shares, when issued and delivered in accordance with the terms of the 2018 Plan, will be validly issued, fully paid and non-assessable.

We understand that you wish to file this opinion with the Commission as an exhibit to the Registration Statement in accordance with the requirements of Item 601(b)(5) of Regulation S-K

---

| |
|:---|
| BOSTON&nbsp;&nbsp;&nbsp;&nbsp; LOS ANGELES&nbsp;&nbsp;&nbsp;&nbsp; MIAMI&nbsp;&nbsp;&nbsp;&nbsp; NEW YORK&nbsp;&nbsp;&nbsp;&nbsp; SAN DIEGO&nbsp;&nbsp;&nbsp;&nbsp; SAN FRANCISCO&nbsp;&nbsp;&nbsp;&nbsp; TORONTO&nbsp;&nbsp;&nbsp;&nbsp; WASHINGTON |
| MINTZ, LEVIN, COHN, FERRIS, GLOVSKY AND POPEO, P.C. |

---

------

---

| | |
|:---|:---|
| **MINTZ** | |
| January 29, 2026<br>Page 2 | ![mintzlogo.jpg](mintzlogo.jpg) |

---

promulgated under the Securities Act, and we hereby consent thereto. In giving this consent, we do not admit that we are within the category of persons whose consent is required under Section 7 of the Securities Act or the rules and regulations of the Commission promulgated thereunder.

---

| |
|:---|
| Very truly yours, |
| /s/ Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. |
| Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. |

---

## Exhibit 23.1

**Exhibit 23.1**

**<u>CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</u>**

As independent registered public accountants, we hereby consent to the use of our report dated March 14, 2025, with respect to the consolidated financial statements of GRI Bio, Inc. for the years ended December 31, 2024 and 2023, in its Registration Statement on Form S-8 pertaining to the registration of 19,907 shares of common stock as described in the prospectus.

*/s/ Sadler, Gibb & Associates, LLC*

Draper, UT

January 29, 2026

<br>